Research study Program year 2025 Source: CMS Open Payments

A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy

Research payments

$652,076

23 payments

Through program year 2025, $652,076 in research payments was reported against A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy, across 23 payments, paid by Vertex Pharmaceuticals Incorporated.

Paid by: Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov: No trial number was reported for this study

By program year

1 row

Year	Kind	Amount	Payments
2025	Research	$652,076	23

Breakdown

Who paid Research payments · program year 2025

Vertex Pharmaceuticals Incorporated $652,076 23 payments

Who received the money Research payments · program year 2025

Bioresearch Partner Organisation paid for research $75,093 1 payment
Ronald Ralph MD PA Organisation paid for research $41,541 1 payment
Davita Clinical Research San Antonio Organisation paid for research $35,714 1 payment
Southwest Kidney Institute Surprise Organisation paid for research $35,644 1 payment
Davita Clinical Research El Paso Organisation paid for research $34,836 1 payment
Kidney Specialists Of Southern Nevada Las Vegas South Rancho Drive Organisation paid for research $34,308 1 payment
Davita Clinical Research Columbus Organisation paid for research $33,897 1 payment
Renal Associates Of Alabama LLC Organisation paid for research $33,868 1 payment
Prolato Clinical Research Center Kirby Dr Organisation paid for research $32,856 1 payment
Ctr Oakwater LLC Organisation paid for research $32,740 1 payment

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

10 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.